Feasibility of Continuous Infusion of Cefiderocol in Conjunction with the Establishment of Therapeutic Drug Monitoring in Patients with Extensively Drug-Resistant Gram-Negative Bacteria
Authors:
- Carolin PrinzCPCarolin Prinz
- Frank StreitFSFrank Streit
- Christian SchumannCSChristian Schumann
- Anna DudakovaADAnna Dudakova
- Christian LanckohrCLChristian Lanckohr
- Julie SchanzJSJulie Schanz
- Matthias BohnMBMatthias Bohn
- Uwe GroßUGUwe Groß
- Konrad MeissnerKMKonrad Meissner
- Onnen MoererOMOnnen Moerer
- Lars-Olav HarnischLHLars-Olav Harnisch
- 5 April 2023
- journal article
- research article
- Published by Springer Nature in Clinical Drug Investigation
- Vol. 43 (4) , 307-314
Abstract
Background and Objective Resistance to antibacterial substances is a huge and still emerging issue, especially with regard to Gram-negative bacteria and in critically ill patients. We report a study in six patients infected with extensively drug-resistant Gram-negative bacteria in a limited outbreak who were successfully managed with a quasi-continuous infusion of cefiderocol. Methods Patients were initially treated with prolonged infusions of cefiderocol over 3 h every 8 h, and the application mode was then switched to a quasi-continuous infusion of 2 g over 8 h, i.e. 6 g in 24 h. Therapeutic drug monitoring (TDM) was established using an in-house liquid chromatography-tandem mass spectrometry (LC-MS/MS) method. Results Determined trough plasma concentrations were a median of 50.00 mg/L [95% confidence interval (CI) 27.20, 74.60] and steady-state plasma concentrations were a median of 90.96 mg/L [95% CI 37.80, 124]. No significant differences were detected with respect to acute kidney injury/continuous renal replacement therapy. Plasma concentrations determined from different modes of storage were almost equal when frozen or cooled, but markedly reduced when stored at room temperature. Conclusions (Quasi) continuous application of cefiderocol 6 g/24 h in conjunction with TDM is a feasible mode of application; the sample for TDM should either be immediately analyzed, cooled, or frozen prior to analysis.Keywords
This publication has 35 references indexed in Scilit:
- Protein Binding of β-Lactam Antibiotics in Critically Ill Patients: Can We Successfully Predict Unbound Concentrations?Antimicrobial Agents and Chemotherapy, 2013
- Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistanceClinical Microbiology and Infection, 2012
- Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distributionJournal of Antimicrobial Chemotherapy, 2009
- Fluid shifts have no influence on ciprofloxacin pharmacokinetics in intensive care patients with intra-abdominal sepsisInternational Journal of Antimicrobial Agents, 2005
- The Changing Face of Antibiotic Prescribing: The Mutant Selection WindowAnnals of Pharmacotherapy, 2004
- A Comparison of Albumin and Saline for Fluid Resuscitation in the Intensive Care UnitNew England Journal of Medicine, 2004
- State‐of‐the‐Art Clinical Article: Pharmacokinetic/Pharmacodynamic Parameters: Rationale for Antibacterial Dosing of Mice and MenClinical Infectious Diseases, 1998
- Pharmacokinetics of antibiotics in natural and experimental superficial compartments in animals and humansJournal of Antimicrobial Chemotherapy, 1993
- Continuous infusion of beta-lactam antibioticsAntimicrobial Agents and Chemotherapy, 1992
- Dosis-Wirkungs-Beziehung der Bakterizidie bei E. coli, K. pneumoniae und Staphylococcus aureusDMW - Deutsche Medizinische Wochenschrift, 1976